Abstract
The B-cell lymphoma, unclassifiable, showing intermediate features typical for both diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (HL) is a novel category of diffuse large B-cell lymphomas (DLBCL/HL), which has been described by the WHO classification in 2008. This rare type of lymphomas, previously called as gray zone lymphoma presents peculiar clinical, morphological and immunophenotypical patterns. In December 2011 a 17-year old male was diagnosed with mixed cellularity subtype of classical HL. His clinical stage was IV/BXS (abdominal bulky) with unfavourable prognosis. Because of the unusally extended disease (nodal-extranodal-bulky) a histological revision was performed. After an incomplete course of ABVD chemotherapy the patient’s symptoms disappeared and regression was detected in the size of peripheral lymph nodes. The diagnosis changed into DLBCL/HL, so the treatment was modified to R-CHOP-14 regimen. After the administration of 3 cycles of R-CHOP-14, he achieved a complete metabolic remission (CMR), which was confirmed by a 18FDG-PET/CT scan. Receiving further 4 cycles of R-CHOP-14 therapy the patient was still in CMR, but a PET negative large mass (70 × 30 mm) still remained visible in the abdominal region. Considering this residuum and the agressive subtype of lymphoma he was referred for an autologous hemopoietic stem cell transplantation (AHSCT). After 2 cycles of R-DHAP regimen, successful CD34 positive stem cell collection was performed in August 2012. In September 2012, he underwent a R-BEAM conditioning followed by AHSCT. The next 18FDG-PET/CT still detected CMR 100 days after the AHSCT. The patient was in excellent clinical condition and also in complete remission 15 months after the AHSCT. Upon this case, it should be underlined that the diagnosis may need revision if a patient represents atypical clinical signs and behavior, and the importance of cooperation between clinicians and pathologists is also strongly emphasized.
Similar content being viewed by others
References
Swerdlow S, Campo E, Harris NL et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. IARC, Lyon, pp 267–268
Grant C, Dunleavy K, Eberle FC et al (2011) Primary mediastinal large B-cell lymphoma, classic hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep 6(3):157–163
Rosenwald A, Wright G, Leroy K et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851–862
Hasserjian RP, Ott G, Elenitoba-Johnson KS et al (2009) Commentary on the WHO classification of tumors of lymphoid tissues (2008)“Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematopathol 2:89–95
Dunleavy K, Grant C, Eberle FC et al (2012) Gray-zone lymphoma: better treated like hodgkin-lymphoma or mediastinal large B-cell lymphoma. Curr Hematol Malig Rep 7:241–247
Cabanillas F (2011) Non-Hodgkin’s lymphoma: the old and the new. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2011.03.029, Epub 2011 Apr 28
Dunleavy K, Pittaluga S, Shovlin M et al (2011) Untreated primary mediastinal B-cell (PMBL) and mediastinal grey zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation. Ann Oncol 22(suppl 4):134
Rieger M, Österborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho D, A, and for the MabThera International Trial (MInT) Group (2011) Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol doi:10.1093/annonc/mdq418
Zinzani PL, Martelli M, Poletti V et al. (2008) Practice guidelines for the management of extranodal non- Hodgkin’s lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. doi: 10.3324/haematol.12742. Epub 2008 Jul 4
Cazals-Hatem D, André M, Munier N et al (2001) Pathologic and clinical features of 77 Hodgkin’s lymphoma patients treated in a lymphoma protocol (LNH87) a GELA study. Am J Surg Pathol 25(3):297–306
Iwaki N, Sato Y, Kurakowa T et al (2013) B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma. Med Mol Morphol. doi:10.1007/s00795-013-0038-8. Epub 2013 Mar 20
Vassilakopuolos PT, Pangalis AG, Katsigiannis A et al (2012) Rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. doi:10.1634/theoncologist
Han HS, Escalo MP, Hsiao B et al (2010) High incidence of falsepositive PET scans in patients with aggressive non Hodgkin lymphoma treated with rituximab containing regimen. Ann Oncol 20:309–318
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Magyari, F., Barna, S., Miltényi, Z. et al. Histopathological Difficulties in an Adolescent Lymphoma Patient. Pathol. Oncol. Res. 21, 213–217 (2015). https://doi.org/10.1007/s12253-014-9810-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-014-9810-x